Biocon Mylan News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Biocon mylan. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Biocon Mylan Today - Breaking & Trending Today
Press release content from Business Wire. The AP news staff was not involved in its creation. Adalimumab: Sold Under the Brand Name Humira - Global Biosimilar Insight Report 2021 - ResearchAndMarkets.com April 2, 2021 GMT The “Adalimumab - Biosimilar Insight, 2021” report has been added to ResearchAndMarkets.com’s offering. This “Adalimumab - Biosimilar Insight, 2021,” report provides comprehensive insights about 34+ companies and 35+ marketed and pipeline drugs in Adalimumab Biosimilars landscape. ADVERTISEMENT It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. ....
Share this article Share this article ResearchAndMarkets.com s offering. The global pegfilgrastim biosimilars market reached a value of nearly $876.0 million in 2019. The market is expected to grow from $876.0 million in 2019 to $1,119.2 million in 2023 at a rate of 6.3%. The growth is mainly due to an increased prevalence of cancer and increased adoption of the biosimilars. The market is expected to stabilize and reach $1,538.6 million in 2025 and $3,598.3 million in 2030. Growth in the historic period resulted from government initiatives for biosimilars, increase in healthcare expenditure, and increase in pharmaceutical R&D expenditure and low costs of biosimilars. This growth was restricted by low rate of drug approvals, and lack of awareness on biosimilars among primary care physicians and specialists. ....